Chardan Capital Maintains Buy on Metagenomi, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating on Metagenomi (NASDAQ:MGX) and maintained a price target of $15.
September 05, 2024 | 7:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating on Metagenomi, maintaining a price target of $15, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $15 price target by Chardan Capital suggests positive sentiment and confidence in Metagenomi's future performance. This could lead to a short-term positive impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100